
BAY94-9027 (Jivi) is approved for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.

BAY94-9027 (Jivi) is approved for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.

Cannabidiol treatment increased the production of inflammatory suppressor cells in mice, which reduced the clinical signs of MS.

Study highlights the importance of understanding, addressing, and bridging gaps in achieving viral suppression.

Top news of the day from across the health care landscape.

The FDA has released a warning on cases of rare, serious genital area infections having been reported with sodium-glucose contransporter-2 (SGLT2) inhibitors.

The evolution of specialty pharmacy has raised the stakes for the services that patients expect during treatment.

A synthetic chemical caused the self-destruction of glioblastoma tumor cells transferred from human patients into mice.

Top news of the day from across the health care landscape.

Study shows the safety and efficacy of treatment with sofosbuvir and velpatasvir in adults with recurrent chronic genotypes 1-4 HCV infection after liver transplant.

The study's findings show that patients with HIV will forgo short travel distances and wait times in order to access a health care provider with a positive attitude.

Researchers investigated whether heavy alcohol consumption in early life was associated with high-grade prostate cancer in adulthood.

Eravacycline is a tetracycline-class antibacterial injection that has demonstrated potent activity against multidrug-resistant pathogens.

Women who carry the BRCA1 and BRCA2 gene mutations are at an increased risk of breast and ovarian cancer, yet many women are unaware of their mutation status.

Top news of the day from across the health care landscape

Amyotrophic lateral sclerosis and frontotemporal dementia exhibit key similarities in underlying molecular mechanisms tied to the dysfunction of RNA-binding proteins.

Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ongoing ESC Congress in Munich, Germany.

Daily aspirin did not reduce the occurrence of major cardiovascular events a study of more than 12,500 participants considered to be at risk.

Substituting brand name combination drugs for lower-cost generics could have reduced spending by $925 million in 2016.

New drug could serve as a potential treatment option for patients who have shown an inadequate response to conventional disease-modifying drugs.

Genetically humanized mice may help researchers develop treatments for hepatitis D virus.

Top news of the day from across the health care landscape

A recent study discovered a new way to use bioinformatics to determine how a patient’s immune system responds to immunotherapy.

Jesse C. Dresser, JD, Partner, Frier & Levitt, LLC, speaks about pharmacy benefit manager-owned specialty pharmacies and how they can impact independent specialty pharmacies.

This week's featured pharmacist is Lisa Lohr, Pharm D, BCPS, BCOP, a Specialty Medication Therapy Management pharmacist specializing in oncology care.

Improved access to uniform cancer care in rural areas could help reduce disparities seen between rural and urban patients.

Top news of the day from across the health care landscape

Molecular link found between aging and a major genetic cause of 2 neurodegenerative disorders.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Lanadelumab (Takhzyro) is the first monoclonal antibody for the treatment of patients 12 years and older with types 1 and 2 hereditary angioedema.